扭亏为盈！4000亿市值A股公司，最新发布

Group 1 - The core viewpoint of the article highlights that BeiGene (688235.SH) reported a total revenue of 38.205 billion yuan for the fiscal year 2025, marking a year-on-year increase of 40.4%, and a net profit attributable to the parent company of 1.422 billion yuan, reversing from a loss to profit [1][2] - The company's product revenue reached 37.770 billion yuan, up from 26.994 billion yuan in the previous year, driven primarily by the sales growth of Brukinsa® (Zebutinib), licensed products from Amgen, and Tislelizumab [1][2] - Global sales of Brukinsa® totaled 28.067 billion yuan, reflecting a year-on-year growth of 48.8%, solidifying its position as a global leader in the BTK inhibitor market [2] Group 2 - The company anticipates that its revenue for 2026 will range between 43.6 billion yuan and 45 billion yuan, with a gross margin expected to remain high at around 80% [2] - Adjusted operating costs for 2026 are projected to be between 9.8 billion yuan and 10.5 billion yuan [2] - As of the market close on the day of the report, BeiGene's stock price fell by 5.65%, with a market capitalization of 405.88 billion yuan [2]